研究人员聚焦于一种新型的固定剂量复方药物，即马西替坦和他达拉非的复方（Macitentan/Tadalafil Fixed-Dose Combination，M/T FDC），这种药物被制成每日服用一次的单药片，旨在为 PAH 患者提供更便捷、有效的治疗方案。该研究成果发表在《Advances in Therapy》上。

Based on the results of SUPER, the FDA-recommended dose for treatment of PAH is 20 mg three-times daily. Tadalafil showed benefit in PAH in the PHIRST trial. [105] This trial enrolled 405 PAH ...

After the FDA approved both combination macitentan/tadalafil (Opsynvi) and the biologic therapy sotatercept (Winrevair) for ...

The panel noted that due to existing commissioning arrangement in place for Targeted Therapies for use in Pulmonary Hypertension in Adults, a NICE TA would not add value and the panel subsequently ...